Prodrugs of STAT3 inhibitors
Provided herein, in certain embodiments, are compounds of Formula I. or a pharmaceutically acceptable salt or a solvate thereof, compositions comprising a compounds of Formula I, or a pharmaceutically acceptable salt or a solvate thereof, and uses thereof such as in treating certain diseases or disorders (e.g., cancer, fibrosis, chronic inflammation).
1. A compound represented by Formula I:
or a pharmaceutically acceptable salt thereof.
2. A pharmaceutical composition comprising:
a) a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and
b) a pharmaceutically acceptable carrier.
3. A method of treating cancer in an individual in need thereof by inhibiting signal transducer and activator of transcription 3 (STAT3), comprising administering to the subject an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
4. The method of claim 3 , wherein the cancer is head and neck cancer, lung cancer, liver cancer, breast cancer, skin cancer, kidney cancer, testicular cancer, colon cancer, rectal cancer, gastric cancer, metastatic melanoma, prostate cancer, ovarian cancer, cervical cancer, bone cancer, spleen cancer, gall bladder cancer, brain cancer, pancreatic cancer, stomach cancer, anal cancer, multiple myeloma, post-transplant lymphoproliferative disease, restenosis, myelodysplastic syndrome, leukemia, or lymphoma.
5. The method of claim 3 , wherein the cancer is head and neck cancer, lung cancer, liver cancer, breast cancer, ovarian cancer, colon cancer, multiple myeloma, leukemia, or pancreatic cancer.
6. A method of treating fibrosis in an individual in need thereof by inhibiting signal transducer and activator of transcription 3 (STAT3), comprising administering to the subject an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
7. The method of claim 6 , wherein the fibrosis is pulmonary fibrosis, bone marrow fibrosis, intestine fibrosis, pancreatic fibrosis, joint fibrosis, liver fibrosis, retroperitoneum fibrosis, renal fibrosis, myelofibrosis, dermal fibrosis, or systemic sclerosis.
8. A method of treating an inflammatory disease or disorder in an individual in need thereof by inhibiting signal transducer and activator of transcription 3 (STAT3), comprising administering to the subject an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
9. The method of claim 8 , wherein the inflammatory disease or disorder is inflammatory bowel disease, ulcerative colitis, psoriasis, uveitis, scleritis, multiple sclerosis, pancreatitis, or asthma.
10. A method of treating a neurodegenerative disease or disorder in an individual in need thereof by inhibiting signal transducer and activator of transcription 3 (STAT3), comprising administering to the subject an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
11. The method of claim 10 , wherein the neurodegenerative disease or disorder is chemotherapy-induced peripheral neuropathy, diabetic neuropathy, or familial amyloid polyneuropathy.
12. A method of treating non-alcoholic fatty liver disease or steatohepatitis in an individual in need thereof by inhibiting signal transducer and activator of transcription 3 (STAT3), comprising administering to the subject an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
13. T A method of treating cachexia in an individual in need thereof by inhibiting signal transducer and activator of transcription 3 (STAT3), comprising administering to the subject an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.
14. A method of treating anaphylaxis in an individual in need thereof by inhibiting signal transducer and activator of transcription 3 (STAT3), comprising administering to the subject an effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof.